iHCK-37
| Code | Size | Price |
|---|
| TAR-T40594-25mg | 25mg | £837.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
iHCK-37 (ASN05260065) is a potent and specific Hck inhibitor with a K i value of 0.22 μM. iHCK-37 blocks HIV-1 viral replication with an EC 50 value of 12.9 μM. iHCK-37 is used for chronic myeloid leukemia (CML) research.
CAS:
516478-09-4
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Fernanda Marconi Roversi, et al. Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway. Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):450-461.
Cristina Tintori, et al. Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents. ChemMedChem. 2013 Aug;8(8):1353-60.